<DOC>
	<DOCNO>NCT01248299</DOCNO>
	<brief_summary>Interest continue systemic chemotherapy , short initial treatment ( 6 week ) patient response stable disease ( `` Discontinuation design `` ) patient metastatic oesophageal cancer squamous cell type The secondary aim would study : toxicity , overall survival rate , study cost quality life .</brief_summary>
	<brief_title>Benefit Chemotherapy Over Best Supportive Care Metastatic Squamous Cell-type Esophageal Cancer .</brief_title>
	<detailed_description>As data litterature provide basis well-argued statistical hypothesis , suggest randomize 30 patient per arm . An IDMC come decision inclusion 10 , 20 an 40 patient efficacy toxicity profile whether maintain current clinical position , justify randomisation . In order take account possible effect prior concomitant radiochemotherapy , patient stratify accord whether already undergone chemotherapy radiochemotherapy .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients histologically proven epidermoid cancer oesophagus Patients metastatic disease measure evaluated accord RECIST criterion , locate outside previously irradiate field Patients may may undergo radiochemotherapy Patients receive chemotherapy metastatic disease ≥ 18 an Performance Status ( ECOG ) ≤ 2 People covered private state health insurance Informed consent sign patient Other evolutive malignant tumor Infection HIV1 , HIV2 chronic hepatitis B C Cerebral metastasis know meningeal tumor Any unstable chronic disease could risk safety compliance te patient Women pregnant breastfeeding . Women must breastfeed least 6 month administration Bevacizumab Patients unable undergo followup trial geographical , social psychological reason For randomized part Inclusion criterion : Nonprogressive disease 6 first week chemotherapy Performance Status ( ECOG ) ≤ 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Best Supportive Care</keyword>
</DOC>